APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
